HRP20211151T1 - Kristalinska tosilatna sol pi3k delta selektivnog inhibitora za uporabu u farmaceutskim formulacijama - Google Patents

Kristalinska tosilatna sol pi3k delta selektivnog inhibitora za uporabu u farmaceutskim formulacijama Download PDF

Info

Publication number
HRP20211151T1
HRP20211151T1 HRP20211151TT HRP20211151T HRP20211151T1 HR P20211151 T1 HRP20211151 T1 HR P20211151T1 HR P20211151T T HRP20211151T T HR P20211151TT HR P20211151 T HRP20211151 T HR P20211151T HR P20211151 T1 HRP20211151 T1 HR P20211151T1
Authority
HR
Croatia
Prior art keywords
disease
cancer
salt
disorder
autoimmune
Prior art date
Application number
HRP20211151TT
Other languages
English (en)
Croatian (hr)
Inventor
Swaroop Kumar Venkata Satya VAKKALANKA
Original Assignee
Rhizen Pharmaceuticals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhizen Pharmaceuticals S.A. filed Critical Rhizen Pharmaceuticals S.A.
Publication of HRP20211151T1 publication Critical patent/HRP20211151T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HRP20211151TT 2014-05-27 2015-05-26 Kristalinska tosilatna sol pi3k delta selektivnog inhibitora za uporabu u farmaceutskim formulacijama HRP20211151T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN2597CH2014 2014-05-27
IN2596CH2014 2014-05-27
EP15733532.4A EP3149000B1 (en) 2014-05-27 2015-05-26 Crystalline tosylate salt of a pi3k delta selective inhibitor for use in pharmaceutical formulations
PCT/IB2015/053940 WO2015181728A1 (en) 2014-05-27 2015-05-26 Improved forms of a pi3k delta selective inhibitor for use in pharmaceutical formulations

Publications (1)

Publication Number Publication Date
HRP20211151T1 true HRP20211151T1 (hr) 2021-10-15

Family

ID=53499042

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20211151TT HRP20211151T1 (hr) 2014-05-27 2015-05-26 Kristalinska tosilatna sol pi3k delta selektivnog inhibitora za uporabu u farmaceutskim formulacijama

Country Status (22)

Country Link
US (4) US9969740B2 (enExample)
EP (2) EP3971188A1 (enExample)
JP (3) JP6987501B2 (enExample)
KR (1) KR20170007480A (enExample)
CN (2) CN111635406A (enExample)
AU (1) AU2015265542B2 (enExample)
BR (1) BR112016027674A2 (enExample)
CA (1) CA2949932C (enExample)
CY (1) CY1124316T1 (enExample)
DK (1) DK3149000T3 (enExample)
EA (1) EA032506B1 (enExample)
ES (1) ES2880999T3 (enExample)
HR (1) HRP20211151T1 (enExample)
HU (1) HUE054916T2 (enExample)
IL (1) IL249058B2 (enExample)
LT (1) LT3149000T (enExample)
PL (1) PL3149000T3 (enExample)
PT (1) PT3149000T (enExample)
RS (1) RS62136B1 (enExample)
SI (1) SI3149000T1 (enExample)
SM (1) SMT202100532T1 (enExample)
WO (1) WO2015181728A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015265542B2 (en) * 2014-05-27 2019-05-09 Rhizen Pharmaceuticals Sa Improved forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations
MX2018014577A (es) 2016-05-27 2019-05-20 Tg Therapeutics Inc Combinacion de anticuerpo anti-cd20, inhibidor selectivo de quinasa p13-delta, e inhibidor de btk para tratar trastornos proliferativos de celulas b.
US20190247399A1 (en) 2016-09-09 2019-08-15 Tg Therapeutics, Inc. Combination of an anti-cd20 antibody, pi3 kinase-delta inhibitor, and anti-pd-1 or anti-pd-l1 antibody for treating hematological cancers
KR20220035169A (ko) * 2019-07-15 2022-03-21 존슨 맛쎄이 퍼블릭 리미티드 컴파니 비정질 움브랄리십 모노토실레이트
WO2022104150A1 (en) 2020-11-12 2022-05-19 Tg Therapeutics, Inc. Triple combination to treat b-cell malignancies
US11965032B1 (en) 2022-06-01 2024-04-23 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11884740B1 (en) 2022-06-01 2024-01-30 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11814439B1 (en) 2022-06-01 2023-11-14 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11807689B1 (en) 2022-06-01 2023-11-07 Tg Therapeutics, Inc. Anti-CD20 antibody compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60144277D1 (de) 2000-04-25 2011-05-05 Icos Corp Hemmer der menschlichen phosphatidyl-inositol-3-kinase delta
HUE035898T2 (en) 2002-12-16 2018-05-28 Genentech Inc Immunoglobulin variants and their applications
US20050043239A1 (en) 2003-08-14 2005-02-24 Jason Douangpanya Methods of inhibiting immune responses stimulated by an endogenous factor
KR20170060179A (ko) 2008-11-13 2017-05-31 길리아드 칼리스토가 엘엘씨 혈액 종양에 대한 요법
AU2010229968A1 (en) 2009-03-24 2011-10-13 Gilead Calistoga Llc Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
JP2012524126A (ja) 2009-04-20 2012-10-11 ギリアド カリストガ リミテッド ライアビリティ カンパニー 固形腫瘍の治療方法
PT2870157T (pt) * 2012-07-04 2017-11-27 Rhizen Pharmaceuticals S A Inibidores seletivos de delta pi3k
AU2015265542B2 (en) * 2014-05-27 2019-05-09 Rhizen Pharmaceuticals Sa Improved forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations

Also Published As

Publication number Publication date
US20190016725A1 (en) 2019-01-17
WO2015181728A1 (en) 2015-12-03
IL249058B (en) 2022-11-01
BR112016027674A2 (pt) 2017-08-15
HUE054916T2 (hu) 2021-10-28
SI3149000T1 (sl) 2021-09-30
EA201692255A1 (ru) 2017-04-28
CA2949932A1 (en) 2015-12-03
US10947244B2 (en) 2021-03-16
RS62136B1 (sr) 2021-08-31
IL249058A0 (en) 2017-01-31
JP2022082680A (ja) 2022-06-02
AU2015265542A1 (en) 2016-12-08
CA2949932C (en) 2021-08-10
ES2880999T3 (es) 2021-11-26
PT3149000T (pt) 2021-07-27
EP3971188A1 (en) 2022-03-23
CY1124316T1 (el) 2022-07-22
PL3149000T3 (pl) 2021-11-02
LT3149000T (lt) 2021-09-10
EP3149000B1 (en) 2021-06-30
JP2020122022A (ja) 2020-08-13
US20170121336A1 (en) 2017-05-04
US9969740B2 (en) 2018-05-15
CN106661030A (zh) 2017-05-10
JP2017516785A (ja) 2017-06-22
SMT202100532T1 (it) 2021-11-12
CN111635406A (zh) 2020-09-08
US10414773B2 (en) 2019-09-17
JP6987501B2 (ja) 2022-01-05
KR20170007480A (ko) 2017-01-18
US20210269446A1 (en) 2021-09-02
US20190382411A1 (en) 2019-12-19
CN106661030B (zh) 2020-06-30
EA032506B1 (ru) 2019-06-28
IL249058B2 (en) 2023-03-01
EP3149000A1 (en) 2017-04-05
AU2015265542B2 (en) 2019-05-09
DK3149000T3 (da) 2021-08-30

Similar Documents

Publication Publication Date Title
HRP20171610T1 (hr) Selektivni inhibitori pi3k delta
JP2019163290A5 (enExample)
JP2017516785A5 (enExample)
JP2017505808A5 (enExample)
JP2016128501A5 (enExample)
HRP20171537T1 (hr) Novi modulatori benzopiran kinaze
JP2019515952A5 (enExample)
JP2016523973A5 (enExample)
JP2010519206A5 (enExample)
JP2019515043A5 (enExample)
JP2010509342A5 (enExample)
JP2019519598A5 (enExample)
CA2669695A1 (en) Tetrahydropyridinyl compounds for inflammation and immune-related uses
JP2019529444A5 (enExample)
HRP20241197T1 (hr) Makrociklični spojevi i primjene istih
JP2018502083A5 (enExample)
CA2491895A1 (en) Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
JP2016508505A5 (enExample)
JP2010535218A5 (enExample)
JP2016537346A5 (enExample)
JP2012504603A5 (enExample)
CN102558279B (zh) 熊果酸-3’-取代丙醇酯衍生物的合成及抗肿瘤活性研究
JP2018162278A (ja) 抗ウイルス化合物の固体形態
JP2024521712A5 (enExample)
JP2015516968A5 (enExample)